Sunshine Biopharma (SBFM) Equity Ratio (2010 - 2026)

Sunshine Biopharma has reported Equity Ratio for 16 years, with the latest figure at 0.77 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 0.96% year-over-year to 0.77; the trailing twelve-month figure through Mar 2026 stood at 0.77 (down 0.96% YoY), and the FY2025 full-year result was 0.77, changed 0.4% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.77, up from 0.77 in the prior quarter.
• The five-year high for Equity Ratio was 1.0 in Q2 2022, with the low at 0.72 in Q1 2023.
• Historically, Equity Ratio has averaged 0.82 across 5 years, with a median of 0.78 in 2024.
• Annual changes were most pronounced in 2022 — Equity Ratio jumped 669.7% — and 2023, when it slipped 27.5%.
• Sunshine Biopharma's Equity Ratio stood at 0.74 in 2022, then climbed by 4.86% to 0.78 in 2023, then fell by 0.84% to 0.77 in 2024, then fell by 0.4% to 0.77 in 2025, then climbed by 0.58% to 0.77 in 2026.
• The last three Equity Ratio figures came in at 0.77 (Q1 2026), 0.77 (Q4 2025), and 0.77 (Q3 2025), per Business Quant data.